Clinical Trial

A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

Name: A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris — clinical trial record (NCT07532603)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ALPINE

Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris

Protocol Amendment History 1 change

notable Trial sites expanded: 5 -> 61 locations 2026-07-09

Trial Details

NCT Number	NCT07532603
Lead Sponsor	Priovant Therapeutics, Inc.
Conditions	Lichen Planopilaris
Enrollment	342 participants
Start Date	2026-03-19
Primary Completion	2028-12-31 (estimated)
Study Completion	2029-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-08